.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 as well as rated another 9 labels in the area as obese. The investment financial institution stated in a note that it continues to strongly believe “diabesity is actually set to come to be.